1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd.

NPNKF
Nippon Shinyaku Co., Ltd.US flagOther OTC
31.40
USD
- -
- -
2.12BMarket Cap
Nippon Shinyaku Co., Ltd.
NPNKF
(Other OTC)

Recent

price

31.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
941.08
997.07
1,036.39
1,134.34
1,186.72
1,249.91
1,466.42
1,506.17
1,703.18
1,731.73
1,809.26
2,041.25
2,140.59
2,201.2
2,379.02
2,535.35
1,112.69
Revenue per Share
58.61
55.04
68.86
85.24
87.26
94.1
174.42
192.31
242.03
250.41
290.11
370.97
338.69
383.82
483.4
441.25
143.65
Basic EPS, GAAP
19.95
37.66
35.39
70.45
71.92
107.03
216.2
37.74
205.66
162.13
302.87
183.7
214.42
98.59
19.79
404.14
38.93
Free Cash Flow per Basic Share
18.97
18.98
20
22
24
27
31.98
55.94
54.9
83.9
91.99
100.95
115.94
118.94
123.95
124.03
61.97
Dividend per Share
1,129.62
1,166.11
1,215.28
1,279.06
1,339.83
1,407.59
1,559.8
1,696.27
1,883.35
2,038.29
2,256.32
2,531.1
2,755.74
3,020.46
3,382.43
3,739.31
3,201.62
Book Value per Share
1,199.78
1,244.38
1,316.74
1,373.12
1,494.67
1,517.86
1,689.71
1,858.84
2,001.02
2,057.24
2,280.74
2,477.01
2,654.32
2,901.39
2,954.98
3,617.01
3,061.16
Tangible Book Value per Share
68
68
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
Basic Weighted Avg Shares
63,550
67,304
69,941
76,517
79,991
84,209
98,781
101,448
114,716
116,637
121,859
137,484
144,175
148,255
160,232
170,771
74,940
Sales/Revenue/Turnover
19.91
8.94
9.87
10.51
10.71
10.16
15.47
16.84
18
18.58
22.32
23.96
20.84
22.46
22.12
20.79
16.57
Operating Margin (%)
3,116
2,948
2,759
2,704
2,665
2,452
2,648
2,773
3,418
3,468
4,400
4,588
5,041
5,023
6,015
6,629
2,561
Depreciation Expense
3,958
3,715
4,647
5,750
5,882
6,340
11,749
12,953
16,302
16,866
19,540
24,986
22,812
25,851
32,558
29,721
9,675
Net Income, GAAP
33.01
39.71
36.41
33
34.04
29.1
23.98
25.68
24.22
24.74
29.15
24.93
25.15
23.09
9.89
18.47
22.4
Effective Tax Rate (%)
6.23
5.52
6.64
7.51
7.35
7.53
11.89
12.77
14.21
14.46
16.03
18.17
15.82
17.44
20.32
17.4
12.91
Profit Margin (%)
47,847
52,372
55,255
59,426
62,652
64,832
71,786
72,722
85,314
94,303
104,857
117,695
122,690
126,949
119,424
140,981
132,114
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
866
1,383
1,219
1,148
1,152
1,374
1,654
1,234
LT Debt
81,692
84,564
89,527
93,185
101,206
102,762
114,316
125,686
135,189
146,860
163,448
180,884
195,931
220,534
247,339
291,869
235,250
Total Equity
10.3
4.29
4.94
5.77
5.67
5.79
10.39
10.3
11.68
11.21
11.9
13.75
11.49
11.86
13.26
10.06
4.21
Return on Invested Capital (%)
5.25
4.77
5.76
6.81
6.64
6.83
11.72
11.78
13.48
12.63
13.31
15.26
12.65
13.21
14.94
12.29
4.72
Return on Capital (%)
5.28
4.79
5.78
6.83
6.66
6.85
11.75
11.81
13.52
12.77
13.51
15.5
12.81
13.29
15.1
12.39
4.68
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
1,720
- -
1,317
LT Borrowings
- -
- -
- -
LT Finance Leases
1,152
- -
1,234
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
- -
67
Market Capitalization
566,622
602,278
537,778

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
164,285
- -
159,826
Cash, Cash Equivalents & STI
68,703
- -
66,020
Accounts Receivable, Net
47,237
- -
43,071
Inventories
39,111
- -
42,805
Total Current Liabilities
37,336
- -
27,712
Payables & Accruals
- -
- -
- -
ST Debt
1,720
- -
1,317
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.04%
12.34%
18%
Free Cash Flow
231.55%
357.1%
1,942.09%
Net Income, GAAP
19.05%
9.94%
-8.71%
Sales/Revenue/Turnover
7.44%
7.04%
6.58%
Total Cash Common Dividend
18.54%
6.29%
0.07%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37,012
36,301
39,413
35,527
148,255
2025
- -
- -
- -
- -
160,232
2026
- -
- -
- -
- -
170,771

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
129.9
110.26
116.2
- -
383.82
2025
- -
- -
- -
- -
483.4
2026
- -
- -
- -
- -
441.25

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
53.82
3.15
58.62
- -
118.94
2025
- -
- -
- -
- -
123.95
2026
- -
- -
- -
- -
124.03
Similar Companies
Medical Developments International Limited (MDDVF)
THC Biomed Intl Ltd. (THCBF)
BioELife Corp. (LITH)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SS)
MGC Pharmaceuticals Limited (MGCLF)
PT Darya-Varia Laboratoria Tbk (DVLA.JK)
Business
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto, founded in 1911, specializing in the development, manufacture, and marketing of prescription drugs and functional foods. The company's core pharmaceutical products include treatments for urological diseases, hematological diseases, intractable or rare diseases such as Duchenne muscular dystrophy, pulmonary arterial hypertension, and gynecological diseases. Key branded drugs consist of Viltepso for Duchenne muscular dystrophy, Uptravi and Opsumit for pulmonary arterial hypertension, Fintepla for seizures linked to severe epileptic syndromes, and multiple cancer treatments including Vyxeos and Jaypirca. The company's functional food segment supplies health food ingredients, preservatives, protein preparations, and sports supplements, serving both domestic and international markets. Nippon Shinyaku operates primarily in Japan but has expanded its presence globally, notably with increased sales in Switzerland and the US. Recent strategic moves include an exclusive license agreement with REGENXBIO to develop and commercialize RGX-121 and RGX-111 for the treatment of Mucopolysaccharidosis II, and a collaboration with Capricor Therapeutics for commercialization of the cell therapy CAP-1002 targeting Duchenne muscular dystrophy. These initiatives are part of Nippon Shinyaku's medium-term management plan, emphasizing global growth from Kyoto and a growing focus on rare and intractable diseases. The company also advanced its oncology portfolio with the launch of new drugs such as Vyxeos and Jaypirca in 2024 while expanding its sales infrastructure in the US and exploring further European market expansion through alliances and potential acquisitions. Nippon Shinyaku combines a broad pharmaceutical portfolio with a functional foods business, positioning itself as a comprehensive healthcare company. Its products address a wide range of therapeutic areas including respiratory, neurological, cardiovascular, and cancer treatments, alongside nutritional and health support products. The company continuously invests in new product development and in-house sales capacity to support global launches and strategic partnerships, reflecting its commitment to innovation and expansion in specialized, high-growth therapeutic segments and global markets. Nippon Shinyaku is listed on the Tokyo Stock Exchange under ticker 4516.T and remains headquartered in Kyoto, Japan.